Targeting of AKT/ERK/CTNNB1 by DAW22 As a Potential Therapeutic Compound for Malignant Peripheral Nerve Sheath Tumor

Overview

Journal Cancer Med

Specialty Oncology

Date 2018 Aug 17

PMID 30112810

Citations 8

Authors

Xiao-Xiao Li

Shi-Jie Zhang

Amy P Chiu

Lilian H Lo

Jian Huang

Dewi K Rowlands

Jinhui Wang

Vincent W Keng

Affiliations

Soon will be listed here.

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are an aggressive form of soft tissue neoplasm with extremely poor prognosis and no effective medical options currently available. MPNSTs can occur either sporadically or in association with the neurofibromatosis type 1 (NF1) syndrome. Importantly, activation of RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, and WNT/CTNNB1 signaling pathways has been reported in both NF1-related and late-stage sporadic MPNSTs. In this study, we found that DAW22, a natural sesquiterpene coumarin compound isolated from Ferula ferulaeoides (Steud.) Korov., could inhibit cell proliferation and colony formation in five established human MPNST cancer cell lines. Further molecular mechanism exploration indicated that DAW22 could target the main components in the MPNST tumorigenic pathways: namely suppress phosphorylation of AKT and ERK, and reduce levels of non-phospho (active) CTNNB1. Using the xenograft mouse model transplanted with human MPNST cancer cell line, daily treatment with DAW22 for 25 days was effective in reducing tumor growth. These results support DAW22 as an alternative therapeutic compound for MPNST treatment by affecting multiple signaling transduction pathways in its disease progression.

Citing Articles

Chemistry, Bioactivity, and Prediction of the Quality Marker (Q-Marker) of Plants in China: A Review.

Bahetjan Y, Muhaxi M, Pang K, Kizaibek M, Tang H, Sefidkon F Molecules. 2023; 28(13).

PMID: 37446853 PMC: 10343754. DOI: 10.3390/molecules28135191.

Research Progress of : A Review.

Chen Z, Zhou G, Ma S Molecules. 2023; 28(8).

PMID: 37110813 PMC: 10145835. DOI: 10.3390/molecules28083579.

Knockdown of NCOR2 Inhibits Cell Proliferation via BDNF/TrkB/ERK in NF1-Derived MPNSTs.

Li Y, Chung M, Aimaier R, Wei C, Wang W, Ge L Cancers (Basel). 2022; 14(23).

PMID: 36497280 PMC: 9738545. DOI: 10.3390/cancers14235798.

Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments.

Amaravathi A, Oblinger J, Welling D, Kinghorn A, Chang L Front Oncol. 2021; 11:698192.

PMID: 34604034 PMC: 8485038. DOI: 10.3389/fonc.2021.698192.

Autophagy is involved in neurofibromatosis type I gene-modulated osteogenic differentiation in human bone mesenchymal stem cells.

Li Y, Zhu M, Lin X, Li J, Yuan Z, Liu Y Exp Ther Med. 2021; 22(5):1262.

PMID: 34603530 PMC: 8453340. DOI: 10.3892/etm.2021.10697.

References

Farid M, Demicco E, Garcia R, Ahn L, Merola P, Cioffi A . Malignant peripheral nerve sheath tumors. Oncologist. 2014; 19(2):193-201. PMC: 3926794. DOI: 10.1634/theoncologist.2013-0328. View

Mahller Y, Vaikunth S, Ripberger M, Baird W, Saeki Y, Cancelas J . Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res. 2008; 68(4):1170-9. PMC: 2855837. DOI: 10.1158/0008-5472.CAN-07-2734. View

Li X, Zhang S, Chiu A, Lo L, Huang J, Rowlands D . Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor. Cancer Med. 2018; 7(9):4791-4800. PMC: 6144169. DOI: 10.1002/cam4.1732. View

Ghadimi M, Lopez G, Torres K, Belousov R, Young E, Liu J . Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2012; 11(8):1758-69. PMC: 3416967. DOI: 10.1158/1535-7163.MCT-12-0015. View

Mahller Y, Rangwala F, Ratner N, Cripe T . Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr Blood Cancer. 2005; 46(7):745-54. DOI: 10.1002/pbc.20565. View

Patwardhan P, Surriga O, Beckman M, de Stanchina E, DeMatteo R, Tap W . Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res. 2014; 20(12):3146-58. PMC: 4060793. DOI: 10.1158/1078-0432.CCR-13-2576. View

Packer R, Rosser T . Therapy for plexiform neurofibromas in children with neurofibromatosis 1: an overview. J Child Neurol. 2002; 17(8):638-41; discussion 646-51. DOI: 10.1177/088307380201700816. View

Watson A, Rahrmann E, Moriarity B, Choi K, Conboy C, Greeley A . Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. Cancer Discov. 2013; 3(6):674-89. PMC: 3679355. DOI: 10.1158/2159-8290.CD-13-0081. View

Holtkamp N, Okuducu A, Mucha J, Afanasieva A, Hartmann C, Atallah I . Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis. 2005; 27(3):664-71. DOI: 10.1093/carcin/bgi273. View

10.

Li Y, Rao P, Wen R, Song Y, Muir D, Wallace P . Notch and Schwann cell transformation. Oncogene. 2004; 23(5):1146-52. DOI: 10.1038/sj.onc.1207068. View

11.

de Toledo S, Azzam E, Dahlberg W, Gooding T, Little J . ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation. Oncogene. 2001; 19(54):6185-93. DOI: 10.1038/sj.onc.1204020. View

12.

Jessen W, Miller S, Jousma E, Wu J, Rizvi T, Brundage M . MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2012; 123(1):340-7. PMC: 3533264. DOI: 10.1172/JCI60578. View

13.

Zhang L, Tong X, Zhang J, Huang J, Wang J . DAW22, a natural sesquiterpene coumarin isolated from Ferula ferulaeoides (Steud.) Korov. that induces C6 glioma cell apoptosis and endoplasmic reticulum (ER) stress. Fitoterapia. 2015; 103:46-54. DOI: 10.1016/j.fitote.2015.03.010. View

14.

Widemann B . Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep. 2009; 11(4):322-8. PMC: 6689400. DOI: 10.1007/s11912-009-0045-z. View

15.

Miller S, Rangwala F, Williams J, Ackerman P, Kong S, Jegga A . Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 2006; 66(5):2584-91. DOI: 10.1158/0008-5472.CAN-05-3330. View

16.

Meng H, Li G, Huang J, Zhang K, Wang H, Wang J . Sesquiterpene coumarin and sesquiterpene chromone derivatives from Ferula ferulaeoides (Steud.) Korov. Fitoterapia. 2013; 86:70-7. DOI: 10.1016/j.fitote.2013.02.002. View

17.

Kraniak J, Sun D, Mattingly R, Reiners Jr J, Tainsky M . The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Mol Cell Biochem. 2010; 344(1-2):267-76. PMC: 3809002. DOI: 10.1007/s11010-010-0551-1. View

18.

Yamashita A, Baia G, Ho J, Velarde E, Wong J, Gallia G . Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors. J Neurooncol. 2014; 118(1):83-92. PMC: 4059766. DOI: 10.1007/s11060-014-1422-5. View

19.

Kim A, Pratilas C . The promise of signal transduction in genetically driven sarcomas of the nerve. Exp Neurol. 2017; 299(Pt B):317-325. DOI: 10.1016/j.expneurol.2017.08.014. View

20.

Demestre M, Terzi M, Mautner V, Vajkoczy P, Kurtz A, Pina A . Effects of pigment epithelium derived factor (PEDF) on malignant peripheral nerve sheath tumours (MPNSTs). J Neurooncol. 2013; 115(3):391-9. DOI: 10.1007/s11060-013-1252-x. View